Print

Purpose

This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Histological or cytological confirmed Metastatic Uveal Melanoma - HLA-A*02:01 negative - No prior systemic therapy in the metastatic or advanced setting, regional or liver-directed therapy, ablations or surgical resection of oligometastatic disease, or neoadjuvant or adjuvant therapy is allowed - Measurable disease per RECIST 1.1 - Able to be safely administered and absorb study therapy - ECOG performance status 0 or 1 - Life expectancy of ≥3 months - Adequate organ function

Exclusion Criteria

  • Previous treatment with a PKC inhibitor (including prior treatment with IDE196), an inhibitor directly targeting MET, or an inhibitor directly targeting GNAQ/11 - Concurrent malignant disease - AEs from prior anti-cancer therapy that have not resolved to Grade ≤1 - Symptomatic or untreated central nervous system (CNS) metastases, or CNS metastases that require corticosteroids - Active HIV infection or Hep B/C - Active adrenal insufficiency, active colitis, or active inflammatory bowel disease - History of interstitial lung disease, active pneumonitis, or history of pneumonitis - Active infection requiring systemic antibiotic therapy - Use of hematopoietic colony-stimulating factors (CSF) prior to start of study drug - Females who are pregnant or breastfeeding - History of severe hypersensitivity reactions (eg, anaphylaxis) to other biologic drugs or monoclonal antibodies - Contraindication for treatment with investigator's choice therapies as per applicable labelling - Has any other condition that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the opinion of the investigator, would make the participant inappropriate for entry into the study

Study Design

Phase
Phase 2/Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Phase 2a Dose Optimization of IDE196 + crizotinib 		Multiple doses of IDE196 will be tested in combination with fixed dose of crizotinib to identify the optimal combination dose.
  • Drug: IDE196
    Dosed orally, twice daily
    Other names:
    • Darovasertib
  • Drug: Crizotinib
    Dosed orally, twice daily
    Other names:
    • XALKORI
Experimental
Phase 2b / 3 Chosen Combination dose of IDE196 + crizotinib 		Chosen combination dose of IDE196 + crizotinib will be tested in additional participants.
  • Drug: IDE196
    Dosed orally, twice daily
    Other names:
    • Darovasertib
  • Drug: Crizotinib
    Dosed orally, twice daily
    Other names:
    • XALKORI
Active Comparator
Phase 2a / 2b / 3 Comparator Arm 		Participants will receive investigator's choice of Pembrolizumab, Ipilimumab + Nivolumab, or Dacarbazine.
  • Drug: Pembrolizumab
    IV administration every 3 weeks
    Other names:
    • Keytruda
  • Drug: Ipilimumab
    IV administration every 3 weeks for 4 Cycles
    Other names:
    • Yervoy
  • Drug: Nivolumab
    IV administration every 3 Weeks for 4 Cycles, thereafter every 4 Weeks maintenance
    Other names:
    • Opdivo
  • Drug: Dacarbazine
    IV administration every 3 Weeks
    Other names:
    • DTIC-Dome

Recruiting Locations

Massachusetts General Hospital
Boston, Massachusetts 02114
Contact:
Kamaneh Montazeri, MD
617-724-4000
kmontazeri@mgh.harvard.edu

More Details

Status
Recruiting
Sponsor
IDEAYA Biosciences

Study Contact

IDEAYA Clinical Trials
1 650-534-3616
IDEAYAClinicalTrials@ideayabio.com

Detailed Description

This study is designed as a multi-stage Phase 2 study within a Phase 3 study to evaluate the safety, tolerability, pharmacokinetics, dose-exposure relationship, and anti-tumor activity of IDE196 in combination with crizotinib compared to the comparator arm of investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine). The Phase 2a dose optimization stage will evaluate two doses of IDE196 in combination with crizotinib compared to the comparator arm. Participants will be randomized to the three treatment arms. At the point of optimal IDE196 + crizotinib dose selection, the other dose arm will be dropped with discontinuation of enrollment to that arm. Participants receiving the IDE196 dose (in combination with crizotinib) that is not selected, will be offered the choice to remain on the same dose or change to the chosen optimal dose. The optimal dose will be chosen to complete the Phase 2b portion. The Phase 2b part of the study will continue to enroll the chosen combination dose of IDE196 + crizotinib compared with the comparator arm. Participants will be randomized to the two treatment arms. The Phase 3 part of the study will continue to enroll the chosen combination dose of IDE196 + crizotinib compared with the comparator arm. Participants will be randomized to the two treatment arms.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.